With the insulin market commoditizing and the coming of a biosimilar short-acting insulin Novo Nordisk (NYSE: NVO) has turned their attention to the expanding GLP-1 market. While Victoza their once daily GLP-1 continues to perform well the company is preparing to do battle in the once-weekly arena. At the moment Trulicity from Lilly (NYSE: LLY) leads this category while Bydureon from AstraZeneca (NYSE: AZN) struggles to compete.
Ozempic, from Novo joins this race and according to a Reuters report will be “included on a 2018 formulary list of acceptable medicines drawn up by Express Script.” This . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.